Hello I'm Raiyyan Tahsan
Brand Model and Executive

TC(1450).(05).Orthopedics Case No 188:-Chronic Posterior Cruciate Ligament Injury with Suspected Post-Traumatic Knee Osteoarthritis Following Previous Tibial Plateau Fracture(1Prescription+0Report+0image)7799

Prescription attached:-

🟧 LIPU MED — FULL CLINICAL CASE REVIEW

āĻŦāĻžāĻ‚āϞāĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟: āĻšāĻžāρāϟ⧁āϰ āĻĒ⧁āϰ⧋āύ⧋ Posterior Cruciate Ligament (PCL) āφāϘāĻžāϤ, āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ Tibial Plateau Fracture-āĻāϰ āχāϤāĻŋāĻšāĻžāϏ āĻāĻŦāĻ‚ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āφāϘāĻžāϤ-āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻšāĻžāρāϟ⧁āϰ āĻ…āĻ¸ā§āϟāĻŋāĻ“āφāĻ°ā§āĻĨā§āϰāĻžāχāϟāĻŋāϏāĨ¤

Confidence: 0.76 — Provisional clinical interpretation

Website Publication Information

ParameterInformation
Proposed TC NumberTC(1447) — Provisional
Department Code(05) Orthopedics
Department Case No.188 — Proposed
Proposed DCSDCS(05)-188 — Provisional internal identifier
Prescription1
Investigation Report0
Clinical Images1 prescription photograph
Original Prescription DateAppears to be 12 September 2016; handwriting uncertain
Review DateWednesday, 28 October 2026
DepartmentOrthopedics & Trauma Surgery
Original PhysicianLt. Col. Dr. Suman Kumar Sen
HospitalMARKS Medical College & Hospital, Dhaka
Review TypeRetrospective clinical and pharmacological analysis

Website verification: raiyyantahsan.com-āĻāϰ Orthopedics archive-āĻ ⧍⧭ āĻ…āĻ•ā§āĻŸā§‹āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ āĻĒā§āϰāĻ•āĻžāĻļāĻŋāϤ āϏāĻ°ā§āĻŦāĻļ⧇āώ āĻĻ⧃āĻļā§āϝāĻŽāĻžāύ Orthopedics case āĻ›āĻŋāϞ TC(1446), Department Case No. 187āĨ¤ āϏ⧇āχ āϧāĻžāϰāĻžāĻŦāĻžāĻšāĻŋāĻ•āϤāĻžā§Ÿ Case No. 188 āĻĒā§āϰāĻ¸ā§āϤāĻžāĻŦ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

Important: TC(1447) āϏāĻžāχāĻŸā§‡āϰ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ global registry-āϤ⧇ āĻ…āĻ¨ā§āϝ āĻŦāĻŋāĻ­āĻžāϗ⧇ āχāϤāĻŋāĻŽāĻ§ā§āϝ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§Ÿā§‡āϛ⧇ āĻ•āĻŋ āύāĻž, āϤāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§ŸāύāĻŋāĨ¤ āĻāϟāĻŋ āĻĒā§āϰāĻ•āĻžāĻļāύāĻžāϰ āϜāĻ¨ā§āϝ āĻĒā§āϰāĻ¸ā§āϤāĻžāĻŦāĻŋāϤ āύāĻŽā§āĻŦāϰ, āύāĻŋāĻŦāĻ¨ā§āϧāĻŋāϤ āĻŦāĻž āϏāĻ‚āϰāĻ•ā§āώāĻŋāϤ āύāĻŽā§āĻŦāϰ āύ⧟āĨ¤

Confidence: 0.90 for the observed Orthopedics sequence; 0.60 for global TC uniqueness.


🟧 PART 1 — ORIGINAL PRESCRIPTION ANALYSIS

1. Patient Information — āϰ⧋āĻ—ā§€āϰ āϤāĻĨā§āϝ

ParameterPrescription FindingConfidence
Name — āύāĻžāĻŽHandwriting unclear; privacy-protected for publication0.55
Age — āĻŦ⧟āϏApproximately 26 years, subject to verification0.65
Sex — āϞāĻŋāĻ™ā§āĻ—Male — āĻĒ⧁āϰ⧁āώ0.96
Consultation Date — āϤāĻžāϰāĻŋāĻ–Possibly 12/09/20160.65
Department — āĻŦāĻŋāĻ­āĻžāĻ—Orthopedics — āĻ…āĻ°ā§āĻĨā§‹āĻĒ⧇āĻĄāĻŋāĻ•āϏ0.99
Clinical context — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻ•āĻžāϰāĻŖPrevious knee injury and degenerative joint disorder0.88

āϰ⧋āĻ—ā§€āϰ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āĻĒāϰāĻŋāϚ⧟ āĻĒā§āϰāĻ•āĻžāĻļ āύāĻž āĻ•āϰ⧇ Patient X āĻšāĻŋāϏ⧇āĻŦ⧇ Case Report āĻĒā§āϰāĻ•āĻžāĻļ āĻ•āϰāĻžāχ āωāĻĒāϝ⧁āĻ•ā§āϤāĨ¤


2. C/C — Chief Complaints — āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—

What the Doctor Documented

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āφāϞāĻžāĻĻāĻž āĻ•āϰ⧇ Chief Complaints āĻŦāĻž āϰ⧋āĻ—ā§€āϰ āύāĻŋāĻœā§‡āϰ āĻ­āĻžāώāĻžā§Ÿ āωāĻĒāϏāĻ°ā§āϗ⧇āϰ āĻŦāĻŋāĻŦāϰāĻŖ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

āϤāĻŦ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύ⧋āϟ āĻ“ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ“āώ⧁āϧāϗ⧁āϞ⧋ āĻĨ⧇āϕ⧇ āĻ•āĻŋāϛ⧁ āωāĻĒāϏāĻ°ā§āĻ— āĻ…āύ⧁āĻŽāĻžāύ āĻ•āϰāĻž āϝāĻžā§ŸāĨ¤

Possible Clinical Complaints — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—

  1. Chronic Knee Pain — āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ⧇āϰ āĻšāĻžāρāϟ⧁āĻŦā§āϝāĻĨāĻžāĨ¤
    Osteoarthritis āĻāĻŦāĻ‚ āĻĒ⧁āϰ⧋āύ⧋ āĻšāĻžāρāϟ⧁āϰ āφāϘāĻžāϤ⧇āϰ āϏāĻ™ā§āϗ⧇ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖāĨ¤ āϤāĻŦ⧇ āĻŦā§āϝāĻĨāĻž āĻ•āϤāĻĻāĻŋāύ⧇āϰ āĻŦāĻž āĻ•āϤāϟāĻž āϤ⧀āĻŦā§āϰ, āϤāĻž āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤
  2. Possible Knee Instability — āĻšāĻžāρāϟ⧁ āĻ…āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞ āĻšāĻ“ā§ŸāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤
    PCL injury āĻĨāĻžāĻ•āϞ⧇ āĻšāĻžāρāϟ⧁ āĻĸāĻŋāϞ⧇ āϞāĻžāĻ—āĻž āĻŦāĻž āĻšāĻžāρāϟ⧁āϰ āĻ“āĻĒāϰ āĻ­āϰ āĻĻāĻŋāϞ⧇ āĻ…āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻž āĻ…āύ⧁āĻ­ā§‚āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  3. Possible Functional Limitation — āĻšāĻžāρāϟ⧁āϰ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻ•āĻžāĻ°ā§āϝāĻ•ā§āώāĻŽāϤāĻž āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤
    āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āĻŸā§‡āϰ āφāϘāĻžāϤ āĻ“ Thigh Muscle Wasting āĻĨāĻžāĻ•āϞ⧇ āĻšāĻžāρāϟāĻž, āϏāĻŋāρ⧜āĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦāĻž āĻĻā§€āĻ°ā§āϘāĻ•ā§āώāĻŖ āĻĻāĻžāρ⧜āĻŋā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻ…āϏ⧁āĻŦāĻŋāϧāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Clinical documentation warning: āĻāϗ⧁āϞ⧋ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āωāĻĒāϏāĻ°ā§āĻ—, āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž āύāĻŋāĻļā§āϚāĻŋāϤ C/C āύ⧟āĨ¤

Confidence: Knee pain 0.82 | Instability 0.65 | Functional limitation 0.60


3. I/H — Illness History — āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ

Documented Information

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϏāĻŽā§āĻ­āĻŦāϤ āϞ⧇āĻ–āĻž āĻ°ā§Ÿā§‡āϛ⧇:

Old PCL Injury — Posterior Cruciate Ligament-āĻāϰ āĻĒ⧁āϰ⧋āύ⧋ āφāϘāĻžāϤāĨ¤

āĻāϟāĻŋ āĻšāĻžāρāϟ⧁āϰ āĻāĻ•āϟāĻŋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻžāĻĻāĻžāύāĻ•āĻžāϰ⧀ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āĻŸā§‡āϰ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āφāϘāĻžāϤ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ•āϰ⧇āĨ¤

Clinical Interpretation

PCL āĻšāĻžāρāϟ⧁āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻĻāĻŋāϕ⧇ Tibia-āĻāϰ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āϏāϰ⧇ āϝāĻžāĻ“ā§ŸāĻž āĻĒā§āϰāϤāĻŋāϰ⧋āϧ āĻ•āϰ⧇āĨ¤

āĻĒ⧁āϰ⧋āύ⧋ PCL injury-āĻāϰ āĻĢāϞ⧇ āĻ•āĻŋāϛ⧁ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻšāĻžāρāϟ⧁āϰ āĻ…āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻž, āĻŽāĻžāĻ‚āϏāĻĒ⧇āĻļāĻŋ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻāĻŦāĻ‚ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āϏāĻŽā§Ÿā§‡ āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ āĻ•ā§āώ⧟āϜāύāĻŋāϤ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Not documented: āφāϘāĻžāϤ⧇āϰ āϤāĻžāϰāĻŋāĻ–, āĻĻ⧁āĻ°ā§āϘāϟāύāĻžāϰ āϧāϰāύ, āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ MRI, āĻ…āĻĒāĻžāϰ⧇āĻļāύ, āĻĢāĻŋāϜāĻŋāĻ“āĻĨ⧇āϰāĻžāĻĒāĻŋ āĻ…āĻĨāĻŦāĻž āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻĢāϞāĻžāĻĢāϞāĨ¤

Confidence: 0.88 for historical PCL injury; 0.75 for its possible contribution to current joint pathology.


4. O/H — Obstetric / Occupational History — āĻĒā§āϰāϏ⧂āϤāĻŋ āĻ…āĻĨāĻŦāĻž āĻĒ⧇āĻļāĻžāĻ—āϤ āχāϤāĻŋāĻšāĻžāϏ

Obstetric History — āĻĒā§āϰāϏ⧂āϤāĻŋ āχāϤāĻŋāĻšāĻžāϏ: āĻĒ⧁āϰ⧁āώ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĒā§āϰāϝ⧋āĻœā§āϝ āύ⧟āĨ¤

Occupational History — āĻĒ⧇āĻļāĻžāĻ—āϤ āχāϤāĻŋāĻšāĻžāϏ: āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχāĨ¤

āĻĒ⧇āĻļāĻžāĻ—āϤ āĻ•āĻžāĻœā§‡āϰ āϧāϰāύ āϜāĻžāύāĻž āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤ āĻĻā§€āĻ°ā§āϘāĻ•ā§āώāĻŖ āĻĻāĻžāρ⧜āĻŋā§Ÿā§‡ āĻĨāĻžāĻ•āĻž, āĻ­āĻžāϰ⧀ āϜāĻŋāύāĻŋāϏ āĻŦāĻšāύ āĻ•āϰāĻž, āĻšāĻžāρāϟ⧁ āĻ­āĻžāρāϜ āĻ•āϰ⧇ āĻ•āĻžāϜ āĻ•āϰāĻž āĻ…āĻĨāĻŦāĻž āϖ⧇āϞāĻžāϧ⧁āϞāĻžā§Ÿ āĻ…āĻ‚āĻļāĻ—ā§āϰāĻšāĻŖ āĻ•āϰāϞ⧇ āĻšāĻžāρāϟ⧁āϰ āωāĻĒāϏāĻ°ā§āĻ— āĻŦāĻžā§œāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.99 that occupational history is not documented.


5. D/H — Drug History — āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ“āώ⧁āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ“āώ⧁āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āχāϤāĻŋāĻšāĻžāϏ āύ⧇āχāĨ¤

āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϚāĻžāϰāϟāĻŋ āĻ“āώ⧁āϧ āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻž āϝāĻžā§Ÿ:

  1. Ternilla 100 mg
  2. Maxpro MUPS 20 mg
  3. Ostocal DX
  4. Arthrosin TS

Important: Prescribed medication āĻāĻŦāĻ‚ Past Drug History āĻāĻ•āχ āĻŦāĻŋāώ⧟ āύ⧟āĨ¤ āĻ…āϤ⧀āϤ⧇ āϰ⧋āĻ—ā§€ āϕ⧋āύ āĻ“āώ⧁āϧ āĻ–ā§‡ā§Ÿā§‡āϛ⧇āύ, āϤāĻž āϜāĻžāύāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤

Confidence: 0.96 for identified brands; 0.99 that past medication history is unavailable.


6. M/H — Menstrual History — āĻŽāĻžāϏāĻŋāϕ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ

āϰ⧋āĻ—ā§€ Male āĻšāĻ“ā§ŸāĻžā§Ÿ Menstrual History āĻĒā§āϰāϝ⧋āĻœā§āϝ āύ⧟āĨ¤

Confidence: 0.99


7. O/G/E — On General Examination — āϏāĻžāϧāĻžāϰāĻŖ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž

āύāĻŋāĻšā§‡āϰ āϤāĻĨā§āϝāϗ⧁āϞ⧋ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋ:

ExaminationEnglish MeaningāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ
BPBlood PressureāϰāĻ•ā§āϤāϚāĻžāĻĒ
PulseHeart RateāĻšā§ƒāĻĻāĻ¸ā§āĻĒāĻ¨ā§āĻĻāύ
TemperatureBody TemperatureāĻļāϰ⧀āϰ⧇āϰ āϤāĻžāĻĒāĻŽāĻžāĻ¤ā§āϰāĻž
BMIBody Mass IndexāωāĻšā§āϚāϤāĻž āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻ“āϜāύ⧇āϰ āϏ⧂āϚāĻ•
PallorClinical pallorāϰāĻ•ā§āϤāĻ¸ā§āĻŦāĻ˛ā§āĻĒāϤāĻžāϰ āĻŦāĻžāĻšā§āϝāĻŋāĻ• āϞāĻ•ā§āώāĻŖ
EdemaSwellingāĻĢā§‹āϞāĻž
General appearanceOverall clinical conditionāϰ⧋āĻ—ā§€āϰ āϏāĻžāĻŽāĻ—ā§āϰāĻŋāĻ• āĻ…āĻŦāĻ¸ā§āĻĨāĻž

Assessment: General examination findings are not documented.

Confidence: 0.99


8. O/S/E — On Systemic Examination — āĻ…āĻ™ā§āĻ—āϤāĻ¨ā§āĻ¤ā§āϰāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ Musculoskeletal Examination-āĻāϰ āĻ•āĻŋāϛ⧁ āϤāĻĨā§āϝ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤

A. Thigh Muscle Wasting — āωāϰ⧁āϰ āĻŽāĻžāĻ‚āϏāĻĒ⧇āĻļāĻŋ āĻļ⧁āĻ•āĻŋā§Ÿā§‡ āϝāĻžāĻ“ā§ŸāĻž

āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύ⧋āĻŸā§‡ āϏāĻŽā§āĻ­āĻŦāϤ Thigh Wasting (+) āϞ⧇āĻ–āĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Definition: Thigh Muscle Wasting āĻšāϞ⧋ āωāϰ⧁āϰ āĻŽāĻžāĻ‚āϏāĻĒ⧇āĻļāĻŋāϰ āĻ†ā§ŸāϤāύ āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻžāĨ¤

Possible causes:

  • āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ āĻšāĻžāρāϟ⧁ āĻ•āĻŽ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻžāĨ¤
  • āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻŦā§āϝāĻĨāĻžāϰ āĻ•āĻžāϰāϪ⧇ Quadriceps inhibitionāĨ¤
  • āĻĒ⧁āϰ⧋āύ⧋ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āϟ āĻŦāĻž āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ āφāϘāĻžāϤāĨ¤
  • āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻšāĻžāρāϟ⧁āϰ āĻ…āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻžāĨ¤

Clinical significance: Thigh wasting āĻāĻ•āϟāĻŋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ findingāĨ¤ āĻāϟāĻŋ āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ functional impairment-āĻāϰ āϏāĻ™ā§āϗ⧇ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖ, āϤāĻŦ⧇ āĻāĻ•āĻž PCL tear āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰ⧇ āύāĻžāĨ¤

Confidence: 0.80

B. PD Test Positive — Posterior Drawer Test āĻĒāϜāĻŋāϟāĻŋāĻ­

āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻžāϟāĻŋ PD Test +ve āĻŦāϞ⧇ āĻŽāύ⧇ āĻšāĻšā§āϛ⧇āĨ¤

Posterior Drawer Test: āĻšāĻžāρāϟ⧁ āĻĒā§āϰāĻžā§Ÿ ⧝ā§Ļ āĻĄāĻŋāĻ—ā§āϰāĻŋ āĻ­āĻžāρāϜ āĻ•āϰ⧇ Tibia āĻĒ⧇āĻ›āύ⧇āϰ āĻĻāĻŋāϕ⧇ āϏāϰ⧇ āϝāĻžā§Ÿ āĻ•āĻŋ āύāĻž āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāĻž āĻšā§ŸāĨ¤

Positive Test: āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāϕ⧇āϰ āϤ⧁āϞāύāĻžā§Ÿ Tibia āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻĒ⧇āĻ›āύ⧇ āϏāϰ⧇ āϗ⧇āϞ⧇ PCL insufficiency āϏāĻ¨ā§āĻĻ⧇āĻš āĻ•āϰāĻž āĻšā§ŸāĨ¤

Clinical significance: Positive Posterior Drawer Test PCL injury-āĻāϰ āĻĒāĻ•ā§āώ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ clinical evidenceāĨ¤

āϤāĻŦ⧇ āĻ›āĻŦāĻŋāϰ handwriting āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤ āĻĒāϰ⧀āĻ•ā§āώāĻžāϟāĻŋ āϏāĻ¤ā§āϝāĻŋāχ Positive āĻ›āĻŋāϞ āĻ•āĻŋ āύāĻž āĻāĻŦāĻ‚ āĻ•āϤāϟāĻž posterior laxity āĻ›āĻŋāϞ, āϤāĻž āĻĒ⧁āύāϰāĻžā§Ÿ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Confidence: 0.76 for transcription; 0.93 for the clinical significance of a confirmed positive test.

C. Other Required Knee Examination

Documented āύ⧟, āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ:

  • Knee ROM — āĻšāĻžāρāϟ⧁ āĻ•āϤāϟāĻž āĻ­āĻžāρāϜ āĻ“ āϏ⧋āϜāĻž āĻ•āϰāĻž āϝāĻžā§ŸāĨ¤
  • Joint-line tenderness — āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ¸ā§āĻĨāĻžāύ⧇ āϚāĻžāĻĒ āĻĻāĻŋāϞ⧇ āĻŦā§āϝāĻĨāĻžāĨ¤
  • Effusion — āĻšāĻžāρāϟ⧁āϤ⧇ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āϤāϰāϞāĨ¤
  • Posterior sag sign — Tibia āĻĒ⧇āĻ›āύ⧇ āĻŦāϏ⧇ āϝāĻžāĻ“ā§ŸāĻžāϰ āϞāĻ•ā§āώāĻŖāĨ¤
  • Quadriceps strength — āωāϰ⧁āϰ āϏāĻžāĻŽāύ⧇āϰ āĻĒ⧇āĻļāĻŋāϰ āĻļāĻ•ā§āϤāĻŋāĨ¤
  • Varus/valgus stability — āĻšāĻžāρāϟ⧁āϰ āĻĒāĻžāĻļ⧇āϰ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āĻŸā§‡āϰ āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻžāĨ¤
  • Neurovascular examination — āĻĒāĻžā§Ÿā§‡āϰ āϰāĻ•ā§āϤāĻĒā§āϰāĻŦāĻžāĻš āĻ“ āĻ¸ā§āύāĻžā§Ÿā§āϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻžāĨ¤

Confidence: 0.95 for the recommended assessment components.


🟧 PART 2 — DOCTOR’S DIAGNOSIS

9. Doctor’s Written Dx — āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻŦāĻžāĻŽ āĻ…āĻ‚āĻļ⧇ āύāĻŋāĻšā§‡āϰ āĻŦāĻŋāώ⧟āϗ⧁āϞ⧋ āϞ⧇āĻ–āĻž āĻ°ā§Ÿā§‡āϛ⧇ āĻŦāϞ⧇ āĻŽāύ⧇ āĻšāĻšā§āϛ⧇āĨ¤

Diagnosis 1

Old PCL Injury — āĻĒ⧁āϰ⧋āύ⧋ Posterior Cruciate Ligament Injury

āĻšāĻžāρāϟ⧁āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻ•ā§āϰ⧁āĻļāĻŋā§Ÿā§‡āϟ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āĻŸā§‡ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āφāϘāĻžāϤāĨ¤

Confidence: 0.89

Diagnosis 2

OA Knee — Osteoarthritis of Knee

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāρāϟ⧁āϰ āĻ…āĻ¸ā§āϟāĻŋāĻ“āφāĻ°ā§āĻĨā§āϰāĻžāχāϟāĻŋāϏ āĻŦāĻž āĻšāĻžāρāϟ⧁āϰ āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ āĻ•ā§āώ⧟āϜāύāĻŋāϤ āϰ⧋āĻ—āĨ¤

Confidence: 0.86

Diagnosis 3

Old Tibial Plateau Fracture — āϟāĻŋāĻŦāĻŋ⧟āĻžāϞ āĻĒā§āĻ˛ā§āϝāĻžāĻŸā§‹āϰ āĻĒ⧁āϰ⧋āύ⧋ āĻĢā§āĻ°ā§āϝāĻžāĻ•āϚāĻžāϰ

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāρāϟ⧁āϰ āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ āύāĻŋāĻšā§‡āϰ āĻ…āĻ‚āĻļ⧇ Tibia āĻšāĻžā§œā§‡āϰ āωāĻĒāϰ⧇āϰ āĻĒ⧃āĻˇā§āϠ⧇ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ­āĻžāĻ™āύāĨ¤

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ Fracture-āĻāϰ āωāĻ˛ā§āϞ⧇āĻ– āϤ⧁āϞāύāĻžāĻŽā§‚āϞāĻ• āĻ¸ā§āĻĒāĻˇā§āϟāĨ¤ āϤāĻŦ⧇ āĻĄāĻžāύ āύāĻž āĻŦāĻžāĻŽ āĻšāĻžāρāĻŸā§â€”āϏ⧇āϟāĻŋ āύāĻŋāĻļā§āϚāĻŋāϤāĻ­āĻžāĻŦ⧇ āĻĒ⧜āĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤

Confidence: 0.88 for fracture history; 0.50 for laterality.


🟩 PART 3 — MY INDEPENDENT CLINICAL ASSESSMENT

10. Final Working Diagnosis — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Primary Working Diagnosis

Chronic Posterior Cruciate Ligament (PCL) Injury / Possible Chronic PCL Insufficiency of the Knee, with Suspected Post-Traumatic Knee Osteoarthritis Following Previous Tibial Plateau Fracture.

āĻŦāĻžāĻ‚āϞāĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

āĻšāĻžāρāϟ⧁āϰ āĻĒ⧁āϰ⧋āύ⧋ Posterior Cruciate Ligament āφāϘāĻžāϤāϜāύāĻŋāϤ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻ…āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻž āĻāĻŦāĻ‚ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ Tibial Plateau Fracture-āĻāϰ āĻĒāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Post-Traumatic OsteoarthritisāĨ¤

Overall Diagnostic Confidence: 0.76 — Provisional, not confirmed.

Why this diagnosis?

āĻāχ āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āĻĒāĻ•ā§āώ⧇ āϚāĻžāϰāϟāĻŋ āĻĒā§āϰāϧāĻžāύ Clinical Clue āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

1. Previous PCL Injury: āĻĒ⧁āϰ⧋āύ⧋ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āĻŸā§‡āϰ āφāϘāĻžāϤ⧇āϰ āχāϤāĻŋāĻšāĻžāϏāĨ¤

2. Previous Tibial Plateau Fracture: āĻšāĻžāρāϟ⧁āϰ āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ āĻšāĻžā§œā§‡ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āφāϘāĻžāϤāĨ¤

3. Possible Positive Posterior Drawer Test: PCL insufficiency-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĒāϰ⧀āĻ•ā§āώāĻžāĻ—āϤ āĻĒā§āϰāĻŽāĻžāĻŖāĨ¤

4. Thigh Muscle Wasting: āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻšāĻžāρāϟ⧁āϰ āϏāĻŽāĻ¸ā§āϝāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āϚāĻŋāĻšā§āύāĨ¤

Clinical Limitation

āĻŦāĻ°ā§āϤāĻŽāĻžāύ MRI, X-ray āĻāĻŦāĻ‚ āĻĒā§‚āĻ°ā§āĻŖāĻžāĻ™ā§āĻ— āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϤāĻĨā§āϝ āĻ›āĻžā§œāĻž Osteoarthritis-āĻāϰ stage, PCL tear-āĻāϰ grade āĻāĻŦāĻ‚ fracture-āĻāϰ healing status āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϏāĻŽā§āĻ­āĻŦ āύ⧟āĨ¤


11. Definition — āϰ⧋āϗ⧇āϰ āϏāĻ‚āĻœā§āĻžāĻž

A. Posterior Cruciate Ligament Injury

Posterior Cruciate Ligament āĻšāϞ⧋ āĻšāĻžāρāϟ⧁āϰ āĻāĻ•āϟāĻŋ āĻļāĻ•ā§āϤāĻŋāĻļāĻžāϞ⧀ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āϟ, āϝāĻž Femur āĻ“ Tibia-āĻāϰ āĻŽāĻ§ā§āϝ⧇ āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻž āĻŦāϜāĻžā§Ÿ āϰāĻžāϖ⧇āĨ¤

āĻāχ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āϟ āφāĻ‚āĻļāĻŋāĻ• āĻŦāĻž āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻ•ā§āώāϤāĻŋāĻ—ā§āϰāĻ¸ā§āϤ āĻšāϞ⧇ āϤāĻžāϕ⧇ PCL Injury āĻŦāϞāĻž āĻšā§ŸāĨ¤

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāρāϟ⧁āϰ āĻĒ⧇āĻ›āύ⧇āϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āĻŸā§‡ āφāϘāĻžāϤ āĻŦāĻž āĻ›āĻŋāĻā§œā§‡ āϝāĻžāĻ“ā§ŸāĻžāĨ¤

B. Post-Traumatic Osteoarthritis

Post-Traumatic Osteoarthritis āĻšāϞ⧋ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ āφāϘāĻžāϤ, āĻĢā§āĻ°ā§āϝāĻžāĻ•āϚāĻžāϰ āĻŦāĻž āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āϟ āĻ•ā§āώāϤāĻŋāϰ āĻĒāϰ āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ Cartilage āĻ“ āϏāĻ‚āĻļā§āϞāĻŋāĻˇā§āϟ āĻ•āĻžāĻ āĻžāĻŽā§‹ā§Ÿ āĻ•ā§āώ⧟āϜāύāĻŋāϤ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύāĨ¤

āĻŦāĻžāĻ‚āϞāĻž: āφāϘāĻžāϤ⧇āϰ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āϏāĻŽā§Ÿā§‡ āĻšāĻžāρāϟ⧁āϰ āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ āĻ•ā§āώ⧟āϜāύāĻŋāϤ āĻŦāĻžāϤāĨ¤

C. Tibial Plateau Fracture

Tibia āĻšāĻžā§œā§‡āϰ āωāĻĒāϰ⧇āϰ āϝ⧇ āĻ…āĻ‚āĻļ āĻšāĻžāρāϟ⧁āϰ Joint Surface āϤ⧈āϰāĻŋ āĻ•āϰ⧇, āϏ⧇āĻ–āĻžāύ⧇ āĻ­āĻžāĻ™āύāϕ⧇ Tibial Plateau Fracture āĻŦāϞāĻž āĻšā§ŸāĨ¤

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāρāϟ⧁āϰ āύāĻŋāĻšā§‡āϰ āĻœā§Ÿā§‡āĻ¨ā§āϟ-āĻĒ⧃āĻˇā§āϠ⧇āϰ āĻšāĻžā§œ āϭ⧇āϙ⧇ āϝāĻžāĻ“ā§ŸāĻžāĨ¤

Confidence: 0.98 for definitions.


12. Etiology & Pathophysiology — āĻ•āĻžāϰāĻŖ āĻ“ āϰ⧋āϗ⧇āϰ āĻŦāĻŋāĻ•āĻžāĻļ

Possible Injury Mechanism

PCL injury āϏāĻžāϧāĻžāϰāĻŖāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇:

  • āĻšāĻžāρāϟ⧁ āĻ­āĻžāρāϜ āĻĨāĻžāĻ•āĻž āĻ…āĻŦāĻ¸ā§āĻĨāĻžā§Ÿ Tibia-āĻāϰ āϏāĻžāĻŽāύ⧇āϰ āĻ…āĻ‚āĻļ⧇ āϏāϰāĻžāϏāϰāĻŋ āφāϘāĻžāϤāĨ¤
  • āϏ⧜āĻ• āĻĻ⧁āĻ°ā§āϘāϟāύāĻžā§Ÿ Dashboard InjuryāĨ¤
  • āϖ⧇āϞāĻžāϧ⧁āϞāĻžā§Ÿ āĻĒā§œā§‡ āϝāĻžāĻ“ā§ŸāĻžāĨ¤
  • āĻšāĻžāρāϟ⧁āϰ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ HyperflexionāĨ¤

Pathophysiology

Previous Trauma → PCL Damage / Tibial Plateau Injury → Altered Knee Biomechanics → Abnormal Joint Loading → Possible Cartilage Degeneration → Post-Traumatic Osteoarthritis

āĻŦāĻžāĻ‚āϞāĻžā§Ÿ:

āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āφāϘāĻžāϤ → āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āϟ āĻŦāĻž āĻšāĻžā§œā§‡āϰ āĻ•ā§āώāϤāĻŋ → āĻšāĻžāρāϟ⧁āϰ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻ­āĻžāϰāĻŦāĻšāύ āĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻžāϰ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ → āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āϚāĻžāĻĒ â†’ Cartilage āĻ•ā§āĻˇā§Ÿā§‡āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž → Post-Traumatic OsteoarthritisāĨ¤

āĻāχ āĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž; āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻāĻŽāύ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āϘāĻŸā§‡āϛ⧇ āĻ•āĻŋ āύāĻž, āϤāĻž imaging āĻ“ clinical assessment āĻĻāĻŋā§Ÿā§‡ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.93 for the established mechanism; 0.75 for its application to this patient.


13. Clinical Features — āϰ⧋āϗ⧇āϰ āϞāĻ•ā§āώāĻŖ

Chronic PCL Injury āĻāĻŦāĻ‚ Post-Traumatic OA-āϤ⧇ āύāĻŋāĻšā§‡āϰ āϞāĻ•ā§āώāĻŖ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇:

Clinical FeatureāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨāĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇
Knee PaināĻšāĻžāρāϟ⧁āĻŦā§āϝāĻĨāĻžāϏāĻŽā§āĻ­āĻžāĻŦā§āϝ, āϏāϰāĻžāϏāϰāĻŋ āϞ⧇āĻ–āĻž āύ⧇āχ
InstabilityāĻšāĻžāρāϟ⧁ āĻĸāĻŋāϞ⧇ āϞāĻžāĻ—āĻžāϏāĻŽā§āĻ­āĻžāĻŦā§āϝ
Thigh Muscle Wastingāωāϰ⧁āϰ āĻŽāĻžāĻ‚āϏāĻĒ⧇āĻļāĻŋ āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻžāϏāĻŽā§āĻ­āĻŦāϤ āωāĻ˛ā§āϞ⧇āĻ– āĻ°ā§Ÿā§‡āϛ⧇
Posterior Drawer PositiveāĻšāĻžāρāϟ⧁āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻ…āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻžāϰ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻĒāϜāĻŋāϟāĻŋāĻ­āϏāĻŽā§āĻ­āĻŦāϤ āωāĻ˛ā§āϞ⧇āĻ– āĻ°ā§Ÿā§‡āϛ⧇
Reduced ROMāĻšāĻžāρāϟ⧁āϰ āύ⧜āĻžāϚ⧜āĻž āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻžāϜāĻžāύāĻž āύ⧇āχ
CrepitusāĻšāĻžāρāϟ⧁ āύāĻžā§œāĻžāϞ⧇ āϘāĻ°ā§āώāϪ⧇āϰ āĻļāĻŦā§āĻĻ āĻŦāĻž āĻ…āύ⧁āĻ­ā§‚āϤāĻŋāϜāĻžāύāĻž āύ⧇āχ
Joint EffusionāĻšāĻžāρāϟ⧁āϤ⧇ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āϤāϰāϞāϜāĻžāύāĻž āύ⧇āχ
Activity-related PaināĻšāĻžāρāϟāĻžāϚāϞāĻžā§Ÿ āĻŦā§āϝāĻĨāĻž āĻŦ⧃āĻĻā§āϧāĻŋāϜāĻžāύāĻž āύ⧇āχ

Confidence: 0.94 for general clinical features; patient-specific confidence varies as shown.


🟧 PART 4 — INVESTIGATIONS

14. Doctor’s Requested Investigations — āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĻ⧇āĻ“ā§ŸāĻž āĻĒāϰ⧀āĻ•ā§āώāĻž

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āύāĻŋāĻšā§‡āϰ āĻ…āĻ‚āĻļ⧇ āϏāĻŽā§āĻ­āĻŦāϤ āĻĻ⧁āϟāĻŋ āĻĒāϰ⧀āĻ•ā§āώāĻž āϞ⧇āĻ–āĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

Investigation 1: MRI of Knee

MRI — Magnetic Resonance Imaging

āĻŦāĻžāĻ‚āϞāĻž: āϚ⧌āĻŽā§āĻŦāĻ•ā§€ā§Ÿ āϤāϰāĻ™ā§āĻ— āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰ⧇ āĻšāĻžāρāϟ⧁āϰ āϭ⧇āϤāϰ⧇āϰ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āϟ, āĻŽā§‡āύāĻŋāĻ¸ā§āĻ•āĻžāϏ āĻāĻŦāĻ‚ āύāϰāĻŽ āϟāĻŋāĻ¸ā§āϝ⧁āϰ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰāĻŋāϤ āĻ›āĻŦāĻŋāĨ¤

Purpose:

  • PCL Injury āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻžāĨ¤
  • Partial āĻŦāĻž Complete Tear āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤
  • Meniscal Injury āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻžāĨ¤
  • Cartilage Damage āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤
  • āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ Ligament Injury āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻžāĨ¤

Doctor’s likely intention: āĻĒ⧁āϰ⧋āύ⧋ PCL injury-āĻāϰ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻ…āĻŦāĻ¸ā§āĻĨāĻž āĻ“ associated internal derangement āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

Confidence: 0.91

Investigation 2: X-ray of Knee

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ X-ray of Knee āĻāĻŦāĻ‚ āϏāĻŽā§āĻ­āĻŦāϤ B/V āĻŦāĻž āĻĻ⧁āϟāĻŋ View āϞ⧇āĻ–āĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāρāϟ⧁āϰ āĻšāĻžā§œ āĻ“ āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ āĻāĻ•ā§āϏ-āϰ⧇āĨ¤

Purpose:

  • Previous Tibial Plateau Fracture-āĻāϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤
  • Joint-space narrowing āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻžāĨ¤
  • Osteophyte āĻŦāĻž āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻšāĻžā§œā§‡āϰ āĻŦ⧃āĻĻā§āϧāĻŋ āĻĻ⧇āĻ–āĻžāĨ¤
  • Malalignment āĻŦāĻž āĻšāĻžā§œā§‡āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāύ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤
  • āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Post-Traumatic Osteoarthritis-āĻāϰ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāĻžāĨ¤

Suggested appropriate views: Weight-bearing AP āĻ“ lateral knee radiographs; āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ viewāĨ¤

Confidence: 0.89 for X-ray being requested; 0.65 for the exact handwritten views.

Additional Investigations — āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻĒāϰ⧀āĻ•ā§āώāĻž

InvestigationPurposeIndication
PCL Stress RadiographPosterior tibial translation āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύClinically significant PCL laxity
Serum Creatinine/eGFRKidney functionOral NSAID āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āφāϗ⧇ āĻā§āρāĻ•āĻŋ āĻĨāĻžāĻ•āϞ⧇
CBCAnaemia āĻŦāĻž systemic abnormalityClinical indication āĻĨāĻžāĻ•āϞ⧇
ESR/CRPInflammatory process āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύInflammatory arthritis āĻŦāĻž infection āϏāĻ¨ā§āĻĻ⧇āĻš āĻšāϞ⧇
Vitamin DVitamin D deficiency āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύDeficiency-āĻāϰ āĻā§āρāĻ•āĻŋ āĻŦāĻž āωāĻĒāϏāĻ°ā§āĻ— āĻĨāĻžāĻ•āϞ⧇

Important: āĻāϗ⧁āϞ⧋ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āύāϤ⧁āύ āĻ•āϰ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āύ⧟āĨ¤ Clinical indication āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻŦāĻŋāĻŦ⧇āĻšā§āϝāĨ¤

Confidence: 0.94


15. Differential Diagnosis — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—

DiagnosisāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨClinical ReasoningConfidence
Chronic PCL InsufficiencyāĻĒ⧁āϰ⧋āύ⧋ PCL āφāϘāĻžāϤ⧇āϰ āĻ•āĻžāϰāϪ⧇ āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻž āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻžHistorical PCL injury āĻ“ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ PD test positive0.83
Post-Traumatic Knee OAāφāϘāĻžāϤ-āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻšāĻžāρāϟ⧁āϰ āĻ…āĻ¸ā§āϟāĻŋāĻ“āφāĻ°ā§āĻĨā§āϰāĻžāχāϟāĻŋāϏPrevious fracture āĻ“ physician-documented OA0.76
Meniscal InjuryāĻšāĻžāρāϟ⧁āϰ āĻŽā§‡āύāĻŋāĻ¸ā§āĻ•āĻžāϏ⧇ āφāϘāĻžāϤPrevious knee trauma; locking history unavailable0.50
Residual Fracture DeformityāĻĒ⧁āϰ⧋āύ⧋ āĻĢā§āĻ°ā§āϝāĻžāĻ•āϚāĻžāϰ⧇āϰ āĻ•āĻžāϰāϪ⧇ āĻšāĻžā§œā§‡āϰ āφāĻ•ā§ƒāϤāĻŋ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύTibial plateau fracture history0.55
Other Ligament InjuryāĻšāĻžāρāϟ⧁āϰ āĻ…āĻ¨ā§āϝ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āĻŸā§‡ āφāϘāĻžāϤCombined injury cannot be excluded0.50

Clinical priority: PCL injury-āĻāϰ āĻ¸ā§āĻĨāĻžā§ŸāĻŋāĻ¤ā§āĻŦ āĻ“ āϗ⧁āϰ⧁āĻ¤ā§āĻŦ āĻāĻŦāĻ‚ Post-Traumatic OA-āĻāϰ āωāĻĒāĻ¸ā§āĻĨāĻŋāϤāĻŋ āϝāĻžāϚāĻžāχ āĻ•āϰāĻžāĨ¤


🟩 PART 5 — DOCTOR’S DX VS INDEPENDENT DX

16. Diagnostic Comparison — āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āϤ⧁āϞāύāĻž

  • đŸŸĸ Old PCL Injury: āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϞāĻŋāĻ–āĻŋāϤ Dx āĻāĻŦāĻ‚ āĻ¸ā§āĻŦāĻžāϧ⧀āύ working assessment āĻāĻ•āĻŽāϤāĨ¤ āϤāĻŦ⧇ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻž āφāĻ‚āĻļāĻŋāĻ• Tear āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤ āύ⧟āĨ¤ Confidence: 0.89
  • đŸŸĸ Knee Osteoarthritis: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• OA Knee āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰ⧇āϛ⧇āύ āĻŦāϞ⧇ āĻŽāύ⧇ āĻšāĻšā§āϛ⧇āĨ¤ āĻ¸ā§āĻŦāĻžāϧ⧀āύ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇āĻ“ OA āϏāĻŽā§āĻ­āĻžāĻŦā§āϝāĨ¤ Confidence: 0.86
  • đŸŸĸ Old Tibial Plateau Fracture: āωāϭ⧟ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻĢā§āĻ°ā§āϝāĻžāĻ•āϚāĻžāϰ⧇āϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦ āĻ¸ā§āĻŦā§€āĻ•ā§ƒāϤāĨ¤ Confidence: 0.88
  • 🟠 Post-Traumatic Osteoarthritis: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϏāĻŽā§āĻ­āĻŦāϤ āĻļ⧁āϧ⧁ OA āϞāĻŋāϖ⧇āϛ⧇āύāĨ¤ āĻ¸ā§āĻŦāĻžāϧ⧀āύ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇ āĻĒ⧁āϰ⧋āύ⧋ āĻĢā§āĻ°ā§āϝāĻžāĻ•āϚāĻžāϰ āĻ“ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āĻŸā§‡āϰ āφāϘāĻžāϤ⧇āϰ āĻ•āĻžāϰāϪ⧇ āĻāϟāĻŋāϕ⧇ Post-Traumatic OA āĻšāĻŋāϏ⧇āĻŦ⧇ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āĻāϟāĻŋ āĻāĻ•āϟāĻŋ clinical inference, āύāĻŋāĻļā§āϚāĻŋāϤ diagnosis āύ⧟āĨ¤ Confidence: 0.76
  • 🟠 Chronic PCL Insufficiency: āĻĒ⧁āϰ⧋āύ⧋ PCL injury āĻāĻŦāĻ‚ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ positive posterior drawer test āĻĨ⧇āϕ⧇ āĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻ…āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ Objective laxity measurement āύ⧇āχāĨ¤ Confidence: 0.72

Final Comparison

Doctor’s Diagnosis and Independent Working Diagnosis: Substantially Similar.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻāĻŦāĻ‚ āĻ¸ā§āĻŦāĻžāϧ⧀āύ Clinical Assessment āĻŽā§‚āϞāϤ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖāĨ¤

āĻĒāĻžāĻ°ā§āĻĨāĻ•ā§āϝ āĻšāϞ⧋ āĻ¸ā§āĻŦāĻžāϧ⧀āύ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇ āϰ⧋āĻ—āϟāĻŋāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āφāϘāĻžāϤāϜāύāĻŋāϤ āĻ•āĻžāϰāĻŖ āĻāĻŦāĻ‚ Chronic Instability-āĻāϰ āĻŦāĻŋāώ⧟āϟāĻŋ āĻ¸ā§āĻĒāĻˇā§āϟ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

Overall Comparison Confidence: 0.86


🟧 PART 6 — MEDICATION REVIEW ACCORDING TO MEDEX BANGLADESH

Table 1: Prescribed Drug Identification

No.Brand NameGeneric NameTherapeutic ClassMedEx Unit Price
1Ternilla 100 mgAceclofenacNSAIDā§ŗ5
2Maxpro MUPS 20 mgEsomeprazoleProton Pump Inhibitorā§ŗ10
3Ostocal DXCalcium + Vitamin D3Mineral & Vitamin Supplementā§ŗ10
4Arthrosin TSGlucosamine Sulfate + ChondroitinStimulation of Cartilage Formationā§ŗ30

Price confidence: 0.99 — MedEx-listed prices checked on 28 October 2026.

Prescription safety note: āĻ›āĻŦāĻŋāϰ handwritten dosing āĻ“ duration āĻĒ⧁āϰ⧋āĻĒ⧁āϰāĻŋ āĻĒāĻžāĻ āϝ⧋āĻ—ā§āϝ āύ⧟āĨ¤ āϤāĻžāχ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž āĻŦāϞ⧇ āϕ⧋āύ⧋ āĻ…āύāĻŋāĻļā§āϚāĻŋāϤ āĻĄā§‹āϜ āĻĻāĻžāĻŦāĻŋ āĻ•āϰāĻž āĻšāĻšā§āϛ⧇ āύāĻžāĨ¤


💊 DRUG 1 — TERNILLA 100 MG

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Aceclofenac 100 mg — āĻāϏāĻŋāĻ•ā§āϞ⧋āĻĢ⧇āύāĻžāĻ•āĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Ternilla — āϟāĻžāϰāύāĻŋāϞāĻžāĨ¤
Manufacturer: Healthcare Pharmaceuticals Ltd.

3. MedEx Alternate Brand — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

A-Pak, Acebid āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ Aceclofenac 100 mg āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄāĨ¤

4. MedEx Therapeutic Class — āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻļā§āϰ⧇āĻŖāĻŋ

Drugs for Osteoarthritis; Drugs used for Rheumatoid Arthritis; Non-steroidal Anti-inflammatory Drugs (NSAIDs).

āĻŦāĻžāĻ‚āϞāĻž: āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ āĻŦā§āϝāĻĨāĻž āĻ“ āĻĒā§āϰāĻĻāĻžāĻš āĻ•āĻŽāĻžāύ⧋āϰ āύāύ-āĻ¸ā§āĻŸā§‡āϰ⧟āĻĄāĻžāϞ āĻ“āώ⧁āϧāĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Phenylacetic acid derivative NSAID.

āĻŦāĻžāĻ‚āϞāĻž: NSAID āĻļā§āϰ⧇āĻŖāĻŋāϰ āĻŦā§āϝāĻĨāĻž āĻ“ āĻĒā§āϰāĻĻāĻžāĻš āĻ•āĻŽāĻžāύ⧋āϰ āĻ“āώ⧁āϧāĨ¤

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis āĻāĻŦāĻ‚ āφāϘāĻžāϤāϜāύāĻŋāϤ āĻŦā§āϝāĻĨāĻž āĻ“ āĻĒā§āϰāĻĻāĻžāĻš āĻ•āĻŽāĻžāύ⧋āĨ¤

7. Why Prescribed in This Patient — āϕ⧇āύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻšāĻžāρāϟ⧁āĻŦā§āϝāĻĨāĻž āĻ“ Osteoarthritis-āϏāĻ‚āĻļā§āϞāĻŋāĻˇā§āϟ āĻĒā§āϰāĻĻāĻžāĻš āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāϪ⧇āϰ āϜāĻ¨ā§āϝāĨ¤

Clinical point: Aceclofenac āĻŦā§āϝāĻĨāĻž āĻ•āĻŽāĻžāϤ⧇ āĻĒāĻžāϰ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ PCL Tear āĻœā§‹ā§œāĻž āϞāĻžāĻ—āĻžā§Ÿ āύāĻžāĨ¤

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Dyspepsia, abdominal pain, nausea, dizziness āĻāĻŦāĻ‚ gastrointestinal irritationāĨ¤

āϗ⧁āϰ⧁āϤāϰ āĻā§āρāĻ•āĻŋāϰ āĻŽāĻ§ā§āϝ⧇ GI bleeding, acute kidney injury āĻāĻŦāĻ‚ cardiovascular complications āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ MedEx

Ternilla 100 mg — MedEx

10. Unit Price, Strip Price & Composition — āĻĻāĻžāĻŽ āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻļāĻ•ā§āϤāĻŋ

Unit Price: ā§ŗ5.00
Strip Price: ā§ŗ50.00
Also available: Ternilla SR 200 mg.

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Aceclofenac Cyclooxygenase enzyme-āĻāϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽ āĻŦāĻžāϧāĻž āĻĻāĻŋā§Ÿā§‡ Prostaglandin synthesis āĻ•āĻŽāĻžā§ŸāĨ¤

āĻĢāϞ⧇ āĻŦā§āϝāĻĨāĻž āĻ“ āĻĒā§āϰāĻĻāĻžāĻš āĻ•āĻŽā§‡āĨ¤

12. Drug Indications — āϰ⧋āĻ—āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŦā§āϝāĻŦāĻšāĻžāϰ

Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis āĻāĻŦāĻ‚ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ Musculoskeletal PaināĨ¤

13. Drug Interactions & Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧ

Anticoagulants, Lithium, Methotrexate, Diuretics āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ NSAID-āĻāϰ āϏāĻ™ā§āϗ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ interaction āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

NSAID-induced asthma, active GI bleeding āĻ…āĻĨāĻŦāĻž NSAID hypersensitivity āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ…āύ⧁āĻĒāϝ⧁āĻ•ā§āϤāĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

Renal disease, liver disease, peptic ulcer, cardiovascular disease āĻāĻŦāĻ‚ uncontrolled hypertension āĻĨāĻžāĻ•āϞ⧇ āĻŦāĻŋāĻļ⧇āώ āϏāϤāĻ°ā§āĻ•āϤāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

MedEx reference adult dose: 100 mg twice daily.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻžāϧāĻžāϰāĻŖ adult reference āĻ…āύ⧁āϝāĻžā§Ÿā§€ ā§§ā§Ļā§Ļ āĻŽāĻŋ.āĻ—ā§āϰāĻž. āĻĻāĻŋāύ⧇ āĻĻ⧁āχāĻŦāĻžāϰāĨ¤

āĻāϟāĻŋ āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āύāĻŋāĻļā§āϚāĻŋāϤ āĻĄā§‹āϜ āύ⧟āĨ¤ OA-āϤ⧇ Oral NSAID āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϞ⧇ Lowest Effective Dose āĻāĻŦāĻ‚ Shortest Possible Duration āĻ…āύ⧁āϏāϰāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

Pregnancy-āϤ⧇ NSAID āĻŦāĻŋāĻļ⧇āώāϤ ⧍ā§Ļ āϏāĻĒā§āϤāĻžāĻšā§‡āϰ āĻĒāϰ āĻā§āρāĻ•āĻŋāĻĒā§‚āĻ°ā§āĻŖ āĻšāϤ⧇ āĻĒāĻžāϰ⧇; āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻžā§Ÿ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĒāϰāĻŋāĻšāĻžāϰ āĻ•āϰāĻž āĻšā§ŸāĨ¤ Lactation-āĻ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

17. Other Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϏāĻ‚āĻŽāĻŋāĻļā§āϰāĻŖ

Aceclofenac-āĻāϰ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ Fixed-Dose Combination āĻŦāĻžāϜāĻžāϰ⧇ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇; āϤāĻŦ⧇ āĻāĻ•āχ Generic-āĻāϰ āĻ…āĻ¨ā§āϝ combination āĻāĻŦāĻ‚ āĻāĻ•āχ āĻ“āώ⧁āϧ⧇āϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ brand āĻāĻ• āĻŦāĻŋāώ⧟ āύ⧟āĨ¤ āĻāχ āĻĒā§āϰāϤāĻŋāĻŦ⧇āĻĻāύ⧇ MedEx-verified monotherapy āĻ“ SR formulation āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

Drug Identification Confidence: 0.99
Patient-specific Indication Confidence: 0.90

Source: MedEx — Ternilla 100 mg.


💊 DRUG 2 — MAXPRO MUPS 20 MG

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Esomeprazole 20 mg — āχāϏ⧋āĻŽāĻŋāĻĒā§āϰāĻžāϜāϞāĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Maxpro MUPS — āĻŽā§āϝāĻžāĻ•ā§āϏāĻĒā§āϰ⧋ āĻŽāĻžāĻĒāϏāĨ¤
Manufacturer: Renata PLC.

3. MedEx Alternate Brand — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Nexum MUPS, Maxima MUPS, Emep MUPSāĨ¤

4. MedEx Therapeutic Class — āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻļā§āϰ⧇āĻŖāĻŋ

Proton Pump Inhibitor (PPI).

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāĻžāĻ•āĻ¸ā§āĻĨāϞ⧀āϰ āĻāϏāĻŋāĻĄ āĻ‰ā§ŽāĻĒāĻžāĻĻāύ āĻ•āĻŽāĻžāύ⧋āϰ āĻ“āώ⧁āϧāĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Substituted Benzimidazole Proton Pump Inhibitor.

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

GERD, Gastric Ulcer, Duodenal Ulcer āĻāĻŦāĻ‚ NSAID-associated gastric ulcer āĻĒā§āϰāϤāĻŋāϰ⧋āϧ āĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

7. Why Prescribed in This Patient — āϕ⧇āύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇

Aceclofenac āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϏāĻŽā§Ÿ āĻĒāĻžāĻ•āĻ¸ā§āĻĨāϞ⧀āϰ āφāϞāϏāĻžāϰ āĻ“ āϜāϟāĻŋāϞāϤāĻžāϰ āĻā§āρāĻ•āĻŋ āĻ•āĻŽāĻžāϤ⧇ Gastroprotection āĻšāĻŋāϏ⧇āĻŦ⧇ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻŦ⧇āĻļāĻŋāĨ¤

āĻāϟāĻŋ āϰ⧋āĻ—ā§€āϰ GERD āĻ°ā§Ÿā§‡āĻ›ā§‡â€”āĻāĻŽāύ āĻĒā§āϰāĻŽāĻžāĻŖ āύ⧟āĨ¤

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Headache, nausea, abdominal pain, diarrhoea, constipationāĨ¤

āĻĻā§€āĻ°ā§āϘāĻŽā§‡ā§ŸāĻžāĻĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇ āĻ•āĻŋāϛ⧁ āϰ⧋āĻ—ā§€āϰ Hypomagnesaemia, Vitamin B12 deficiency āĻ…āĻĨāĻŦāĻž āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϜāϟāĻŋāϞāϤāĻžāϰ āĻā§āρāĻ•āĻŋ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ MedEx

Maxpro MUPS 20 mg — MedEx

10. Unit Price, Strip Price & Composition — āĻĻāĻžāĻŽ āĻ“ āĻļāĻ•ā§āϤāĻŋ

Unit Price: ā§ŗ10.00
Strip Price: ā§ŗ140.00
Also available: Maxpro MUPS 40 mg.

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Gastric Parietal Cell-āĻāϰ Hâē/Kâē-ATPase Proton Pump āĻŦāĻ¨ā§āϧ āĻ•āϰ⧇ Acid Secretion āĻ•āĻŽāĻžā§ŸāĨ¤

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāĻžāĻ•āĻ¸ā§āĻĨāϞ⧀āϰ āĻāϏāĻŋāĻĄ āϤ⧈āϰāĻŋāϰ āĻĒā§āϰāϧāĻžāύ āĻāύāϜāĻžāχāĻŽā§‡āϰ āĻ•āĻžāϜ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧇āĨ¤

12. Drug Indications — āϰ⧋āĻ—āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŦā§āϝāĻŦāĻšāĻžāϰ

GERD, Erosive Esophagitis, Peptic Ulcer āĻāĻŦāĻ‚ NSAID-associated gastric ulcer preventionāĨ¤

13. Drug Interactions & Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧ

Clopidogrel-āĻāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž āĻ•āĻŽāĻžāύ⧋āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž, Warfarin monitoring-āĻāϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ, Methotrexate interaction āĻāĻŦāĻ‚ āĻ•āĻŋāϛ⧁ āĻ“āώ⧁āϧ⧇āϰ absorption āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ⧇āϰ āĻā§āρāĻ•āĻŋ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Known hypersensitivity āĻāĻ•āϟāĻŋ contraindicationāĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

Severe hepatic disease, unexplained weight loss, GI bleeding āĻāĻŦāĻ‚ āĻĻā§€āĻ°ā§āϘāĻŽā§‡ā§ŸāĻžāĻĻāĻŋ PPI āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

MedEx reference: NSAID-associated gastric ulcer risk reduction-āĻāϰ āϜāĻ¨ā§āϝ Esomeprazole 20 mg once daily āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§ŸāĨ¤

MUPS tablet āϚāĻŋāĻŦāĻžāύ⧋ āĻŦāĻž āϗ⧁āρ⧜āĻž āĻ•āϰāĻž āωāϚāĻŋāϤ āύ⧟āĨ¤ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϞ⧇ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄā§‡āϰ āĻ…āύ⧁āĻŽā§‹āĻĻāĻŋāϤ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĒāĻžāύāĻŋāϤ⧇ disperse āĻ•āϰāĻž āϝāĻžā§ŸāĨ¤

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

Pregnancy āĻ“ lactation-āĻ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ Risk–Benefit Assessment āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

17. Other Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϏāĻ‚āĻŽāĻŋāĻļā§āϰāĻŖ

MedEx-āĻ Esomeprazole-āĻāϰ āϏāĻ™ā§āϗ⧇ Naproxen āĻāĻŦāĻ‚ H. pylori eradication-āĻāϰ āϜāĻ¨ā§āϝ Amoxicillin āĻ“ Clarithromycin-āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ combination formulations āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Drug Identification Confidence: 0.99
Reason for Prescription Confidence: 0.94

Source: MedEx — Maxpro MUPS 20 mg.


💊 DRUG 3 — OSTOCAL DX

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Conventional Calcium + Vitamin D3.

Composition: Elemental Calcium 600 mg + Vitamin D3 400 IU.

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Ostocal DX — āĻ…āĻ¸ā§āĻŸā§‹āĻ•ā§āϝāĻžāϞ āĻĄāĻŋāĻāĻ•ā§āϏāĨ¤
Manufacturer: Eskayef Pharmaceuticals Ltd.

3. MedEx Alternate Brand — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Ostogen D Forte, Ostoplus-DX āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ Calcium–Vitamin D formulationsāĨ¤

4. MedEx Therapeutic Class — āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻļā§āϰ⧇āĻŖāĻŋ

Specific Mineral & Vitamin Combined Preparations.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ–āύāĻŋāϜ āĻ“ āĻ­āĻŋāϟāĻžāĻŽāĻŋāύ⧇āϰ āϏāĻŽāĻ¨ā§āĻŦāĻŋāϤ āϏāĻžāĻĒā§āϞāĻŋāĻŽā§‡āĻ¨ā§āϟāĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Mineral Supplement + Fat-Soluble Vitamin.

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Calcium āĻ“ Vitamin D deficiency āϏāĻ‚āĻļā§‹āϧāύ, Osteoporosis āĻ“ Osteomalacia management-āĻāϰ āϏāĻšāĻžā§ŸāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

7. Why Prescribed in This Patient — āϕ⧇āύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇

āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ Fracture-āĻāϰ āχāϤāĻŋāĻšāĻžāϏ⧇āϰ āĻ•āĻžāϰāϪ⧇ āĻšāĻžā§œā§‡āϰ āĻĒ⧁āĻˇā§āϟāĻŋāĻ—āϤ āϏāĻšāĻžā§ŸāϤāĻžāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Important: Calcium āĻ“ Vitamin D supplement āϏāϰāĻžāϏāϰāĻŋ PCL Tear āĻ…āĻĨāĻŦāĻž Knee Osteoarthritis āϏāĻžāϰāĻžā§Ÿ āύāĻžāĨ¤

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Constipation, nausea, abdominal discomfortāĨ¤

āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻ—ā§āϰāĻšāϪ⧇ Hypercalcaemia āĻāĻŦāĻ‚ Kidney Stone-āĻāϰ āĻā§āρāĻ•āĻŋ āĻŦāĻžā§œāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ MedEx

Ostocal DX — MedEx

10. Unit Price, Strip Price & Composition — āĻĻāĻžāĻŽ āĻ“ āĻļāĻ•ā§āϤāĻŋ

Unit Price: ā§ŗ10.00
Strip Price: ā§ŗ60.00
Also available: Ostocal D 500 mg + 200 IUāĨ¤

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Calcium āĻšāĻžā§œā§‡āϰ Mineralisation-āĻ āĻ…āĻ‚āĻļāĻ—ā§āϰāĻšāĻŖ āĻ•āϰ⧇āĨ¤

Vitamin D3 āĻ…āĻ¨ā§āĻ¤ā§āϰ āĻĨ⧇āϕ⧇ Calcium Absorption āĻŦāĻžā§œāĻžā§Ÿ āĻāĻŦāĻ‚ Calcium Homeostasis āĻŦāϜāĻžā§Ÿ āϰāĻžāĻ–āϤ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇āĨ¤

12. Drug Indications — āϰ⧋āĻ—āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŦā§āϝāĻŦāĻšāĻžāϰ

Calcium deficiency, Vitamin D deficiency, Osteoporosis, Osteomalacia āĻāĻŦāĻ‚ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ Metabolic Bone DisordersāĨ¤

13. Drug Interactions & Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧ

Tetracyclines, āĻ•āĻŋāϛ⧁ Quinolone Antibiotics, Levothyroxine, Digoxin āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ Calcium/Vitamin D preparation-āĻāϰ āϏāĻ™ā§āϗ⧇ interaction āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻšā§ŸāĨ¤

Hypercalcaemia āĻ“ āĻ•āĻŋāϛ⧁ āϧāϰāύ⧇āϰ Renal Stone Disease-āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ…āύ⧁āĻĒāϝ⧁āĻ•ā§āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

Chronic Kidney Disease, Hypercalciuria, Kidney Stones āĻāĻŦāĻ‚ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ Vitamin D āĻ—ā§āϰāĻšāϪ⧇āϰ āĻā§āρāĻ•āĻŋ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

MedEx-āĻ Calcium–Vitamin D preparation-āĻāϰ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ strength āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻ­āĻŋāĻ¨ā§āύ dosing āĻĻ⧇āĻ“ā§ŸāĻž āφāϛ⧇āĨ¤

āĻāχ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āĻ—ā§€āϰ handwritten dose āĻ…āĻ¸ā§āĻĒāĻˇā§āϟāĨ¤ āϤāĻžāχ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻŽā§‹āϟ Dietary Calcium Intake āĻāĻŦāĻ‚ Supplement Dose āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

āĻĒā§āĻ°ā§Ÿā§‹āϜāύ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžā§ŸāĨ¤ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ Calcium/Vitamin D āĻā§œāĻŋā§Ÿā§‡ āϚāϞāϤ⧇ āĻšāĻŦ⧇āĨ¤

17. Other Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϏāĻ‚āĻŽāĻŋāĻļā§āϰāĻŖ

Calcium + Vitamin D3 + Multiminerals āĻāĻŦāĻ‚ Calcium-āĻāϰ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻŋ MedEx-āĻ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Drug Identification Confidence: 0.99
Patient-specific Indication Confidence: 0.72

Source: MedEx — Ostocal DX.


💊 DRUG 4 — ARTHROSIN TS

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Glucosamine Sulfate 750 mg + Chondroitin 600 mg.

āĻŦāĻžāĻ‚āϞāĻž: āĻ—ā§āϞ⧁āϕ⧋āϏāĻžāĻŽāĻŋāύ āϏāĻžāϞāĻĢ⧇āϟ āĻ“ āĻ•āύāĻĄā§āϰ⧟āϟāĻŋāύāĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Arthrosin TS — āφāĻ°ā§āĻĨā§āϰ⧋āϏāĻŋāύ āϟāĻŋāĻāϏāĨ¤

Manufacturer: UniMed UniHealth Pharmaceuticals Ltd.

3. MedEx Alternate Brand — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Arth-A TS, Carticare TS, Synflex TS āĻāĻŦāĻ‚ āĻ…āύ⧁āϰ⧂āĻĒ Glucosamine–Chondroitin combinationāĨ¤

4. MedEx Therapeutic Class — āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻļā§āϰ⧇āĻŖāĻŋ

Stimulation of Cartilage Formation.

āĻŦāĻžāĻ‚āϞāĻž: Cartilage formation-āĻāϰ āϏāĻšāĻžā§ŸāĻ• āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻŋ āĻšāĻŋāϏ⧇āĻŦ⧇ āĻļā§āϰ⧇āĻŖāĻŋāĻŦāĻĻā§āϧāĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Symptomatic Slow-Acting Joint Supplement / Glycosaminoglycan-related Preparation.

6. Use/Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

MedEx āĻ…āύ⧁āϝāĻžā§Ÿā§€ Osteoarthritis-āĻ Joint Supplement āĻšāĻŋāϏ⧇āĻŦ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšā§ŸāĨ¤

7. Why Prescribed in This Patient — āϕ⧇āύ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇

āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϏāĻŽā§āĻ­āĻŦāϤ Knee Osteoarthritis-āĻāϰ āωāĻĒāϏāĻ°ā§āĻ— āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāĻŖ āĻ“ āĻœā§Ÿā§‡āĻ¨ā§āĻŸā§‡āϰ āϏāĻšāĻžā§ŸāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻšāĻŋāϏ⧇āĻŦ⧇ Arthrosin TS āĻĻāĻŋā§Ÿā§‡āϛ⧇āύāĨ¤

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Nausea, abdominal discomfort, flatulence āĻāĻŦāĻ‚ āĻ•āĻŋāϛ⧁ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ allergic reactionāĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ MedEx

Arthrosin TS — MedEx

10. Unit Price, Strip Price & Composition — āĻĻāĻžāĻŽ āĻ“ āĻļāĻ•ā§āϤāĻŋ

Unit Price: ā§ŗ30.00
Strip Price: ā§ŗ180.00
Also available: Arthrosin 250 mg + 200 mgāĨ¤

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Glucosamine āĻ“ Chondroitin āĻšāϞ⧋ Cartilage Matrix-āĻāϰ Glycosaminoglycan-āϏāĻ‚āĻļā§āϞāĻŋāĻˇā§āϟ āωāĻĒāĻžāĻĻāĻžāύāĨ¤

āϤāĻžāĻ¤ā§āĻ¤ā§āĻŦāĻŋāĻ•āĻ­āĻžāĻŦ⧇ Cartilage metabolism āĻ“ Proteoglycan synthesis-āĻ āĻ­ā§‚āĻŽāĻŋāĻ•āĻž āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āϤāĻŦ⧇ Supplement āĻ—ā§āϰāĻšāĻŖ āĻ•āϰāϞ⧇ clinically meaningful Cartilage Regeneration āĻšā§Ÿâ€”āĻāĻŽāύ āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝ āĻĒā§āϰāĻŽāĻžāĻŖ āĻĒā§āϰāϤāĻŋāĻˇā§āĻ āĻŋāϤ āύ⧟āĨ¤

12. Drug Indications — āϰ⧋āĻ—āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŦā§āϝāĻŦāĻšāĻžāϰ

MedEx product information āĻ…āύ⧁āϝāĻžā§Ÿā§€ Knee, Hip āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ Joint Osteoarthritis-āĻ Supplement āĻšāĻŋāϏ⧇āĻŦ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§ŸāĨ¤

13. Drug Interactions & Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧ

Warfarin-āĻāϰ āϏāĻ™ā§āϗ⧇ Bleeding Risk āĻŦ⧃āĻĻā§āϧāĻŋ āĻĒ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Glucosamine āĻŦāĻž Chondroitin-āĻāϰ āωāĻĒāĻžāĻĻāĻžāύ⧇ hypersensitivity āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§œāĻŋā§Ÿā§‡ āϚāϞāϤ⧇ āĻšāĻŦ⧇āĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

Diabetes, Severe Renal Disease āĻāĻŦāĻ‚ Liver Disease āĻĨāĻžāĻ•āϞ⧇ āϏāϤāĻ°ā§āĻ•āϤāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

MedEx reference: 750 mg + 600 mg, one tablet twice daily.

āĻāϟāĻŋ āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻ•āĻžāϰāϕ⧇āϰ reference dose; āĻāχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āύāϤ⧁āύ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āύ⧟āĨ¤

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

āĻĒāĻ°ā§āϝāĻžāĻĒā§āϤ Safety Data āύ⧇āχāĨ¤ āϤāĻžāχ Pregnancy āĻ“ Lactation-āĻ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻā§œāĻŋā§Ÿā§‡ āϚāϞāĻž āωāϚāĻŋāϤāĨ¤

17. Other Combinations — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϏāĻ‚āĻŽāĻŋāĻļā§āϰāĻŖ

MedEx-āĻ Glucosamine Sulfate + Diacerein āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ Glucosamine-containing formulations āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

🟠 Important Guideline Difference

MedEx product information-āĻ Arthrosin TS-āĻāϰ OA-related indication āωāĻ˛ā§āϞ⧇āĻ– āĻĨāĻžāĻ•āϞ⧇āĻ“ NICE NG226 Glucosamine āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻž āĻ•āϰāĻžāϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻĻā§‡ā§ŸāĨ¤

āĻ•āĻžāϰāĻŖ Osteoarthritis-āĻāϰ āωāĻĒāϏāĻ°ā§āϗ⧇ clinically meaningful benefit-āĻāϰ āĻļāĻ•ā§āϤ āĻĒā§āϰāĻŽāĻžāĻŖ āύ⧇āχāĨ¤

Therefore: MedEx therapeutic classification āĻŦāĻž manufacturer’s indication-āϕ⧇ āφāĻ¨ā§āϤāĻ°ā§āϜāĻžāϤāĻŋāĻ• Guideline-supported effectiveness-āĻāϰ āϏāĻŽāϤ⧁āĻ˛ā§āϝ āϧāϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Drug Identification Confidence: 0.99
Evidence-based Routine Use in OA: Not Recommended by NICE — Confidence 0.98


🟩 PART 7 — BANGLADESH DRUG OPTIONS

Table 2: MedEx-Listed Examples for Knee Osteoarthritis and Related Conditions

āύāĻŋāĻšā§‡āϰ āĻ“āώ⧁āϧāϗ⧁āϞ⧋ āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇ MedEx-āĻ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤāĨ¤ āĻāϗ⧁āϞ⧋ āĻāĻ•āχ āϰ⧋āϗ⧇ āϏāĻŦ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āωāĻĒāϝ⧁āĻ•ā§āϤ āύ⧟ āĻāĻŦāĻ‚ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āϰ⧋āĻ—ā§€āϰ āωāĻĒāϏāĻ°ā§āĻ—, āχāϤāĻŋāĻšāĻžāϏ āĻ“ āĻā§āρāĻ•āĻŋ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āύāĻŋāϤ⧇ āĻšā§ŸāĨ¤

No.Drug / Brand ExamplesGeneric / ClassClinical PurposeImportant Note
1Diclofenac topical formulationsTopical NSAIDLocal knee pain relief — āĻšāĻžāρāϟ⧁āϰ āĻ¸ā§āĻĨāĻžāĻ¨ā§€ā§Ÿ āĻŦā§āϝāĻĨāĻž āĻ•āĻŽāĻžāύ⧋NICE first-line pharmacological option
2Ternilla, AcebidAceclofenacPain and inflammationGI, renal, cardiovascular risk
3Other licensed NSAID brandsNSAIDShort-term symptom reliefAvoid unnecessary duplicate NSAIDs
4Maxpro MUPS, Nexum MUPSEsomeprazoleOral NSAID āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇ GastroprotectionOA-āĻāϰ āĻŽā§‚āϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύ⧟
5Ostocal DX, Ostogen D ForteCalcium + Vitamin DDeficiency āĻŦāĻž bone-health indicationRoutine OA cure āύ⧟
6Arthrosin TS, Arth-A TSGlucosamine + ChondroitinJoint supplementsNICE does not recommend glucosamine for OA

MedEx Generic Directories

1. Aceclofenac alternatives:
MedEx Aceclofenac Brand List

2. Esomeprazole MUPS alternatives:
MedEx Esomeprazole MUPS Brand List

3. Calcium + Vitamin D alternatives:
MedEx Calcium and Vitamin D Brand List

4. Glucosamine + Chondroitin alternatives:
MedEx Glucosamine and Chondroitin Brand List

Evidence Confidence: 0.96 for MedEx classification; prescribing appropriateness must be assessed individually.


🟧 PART 8 — MANAGEMENT ACCORDING TO GUIDELINES

17. Management / Treatment — āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻž

A. Conservative Management — āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž

1. Supervised Physiotherapy — āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžā§‡āϰ āϤāĻ¤ā§āĻ¤ā§āĻŦāĻžāĻŦāϧāĻžāύ⧇ āĻĢāĻŋāϜāĻŋāĻ“āĻĨ⧇āϰāĻžāĻĒāĻŋ

Quadriceps strengthening, controlled knee rehabilitation āĻāĻŦāĻ‚ functional trainingāĨ¤

āĻŦāĻžāĻ‚āϞāĻž: āωāϰ⧁āϰ āϏāĻžāĻŽāύ⧇āϰ āĻŽāĻžāĻ‚āϏāĻĒ⧇āĻļāĻŋ āĻļāĻ•ā§āϤāĻŋāĻļāĻžāϞ⧀ āĻ•āϰāĻž āĻāĻŦāĻ‚ āĻšāĻžāρāϟ⧁āϰ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻ•āĻžāĻ°ā§āϝāĻ•ā§āώāĻŽāϤāĻž āĻĒ⧁āύāϰ⧁āĻĻā§āϧāĻžāϰāĨ¤

2. Activity Modification — āĻ•āĻžāϜāĻ•āĻ°ā§āĻŽā§‡āϰ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ

āĻšāĻžāρāϟ⧁āϰ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āϚāĻžāĻĒ āϏ⧃āĻˇā§āϟāĻŋ āĻ•āϰ⧇ āĻāĻŽāύ āĻ•āĻžāϜ āϏāĻžāĻŽā§ŸāĻŋāĻ•āĻ­āĻžāĻŦ⧇ āϏ⧀āĻŽāĻŋāϤ āĻ•āϰāĻžāĨ¤

3. Weight Management — āĻ“āϜāύ āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāĻŖ

āϰ⧋āĻ—ā§€ Overweight āĻšāϞ⧇ āĻ“āϜāύ āĻ•āĻŽāĻžāύ⧋ Knee OA-āĻāϰ āωāĻĒāϏāĻ°ā§āĻ— āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāϪ⧇ āϏāĻšāĻžā§ŸāĻ•āĨ¤

4. Pain Management — āĻŦā§āϝāĻĨāĻžāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž

Knee OA-āϤ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϞ⧇ Topical NSAID guideline-supported āĻĒā§āϰāĻĨāĻŽ Pharmacological OptionāĨ¤

Oral NSAID āĻŦāĻŋāĻŦ⧇āϚāύāĻžāϰ āϏāĻŽā§Ÿ GI, Renal āĻāĻŦāĻ‚ Cardiovascular Risk āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

5. Knee Bracing — āĻšāĻžāρāϟ⧁āϰ āĻŦā§āϰ⧇āϏ

Documented Instability āĻĨāĻžāĻ•āϞ⧇ āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžā§‡āϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ⧇ Appropriate PCL Brace āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āϝāĻžā§ŸāĨ¤

B. Surgical Evaluation — āĻ…āĻ¸ā§āĻ¤ā§āϰ⧋āĻĒāϚāĻžāϰ⧇āϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

āύāĻŋāĻšā§‡āϰ āĻĒāϰāĻŋāĻ¸ā§āĻĨāĻŋāϤāĻŋāϤ⧇ Knee Surgeon-āĻāϰ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇:

  • Persistent symptomatic instabilityāĨ¤
  • Significant PCL laxityāĨ¤
  • Associated multiple-ligament injuryāĨ¤
  • Persistent pain despite structured rehabilitationāĨ¤
  • Severe function-limiting Post-Traumatic OAāĨ¤

Important: PCL injury āĻĨāĻžāĻ•āϞ⧇āχ āĻ…āĻ¸ā§āĻ¤ā§āϰ⧋āĻĒāϚāĻžāϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšā§Ÿ āύāĻžāĨ¤ Injury severity, functional limitation āĻāĻŦāĻ‚ associated injuries āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āύāĻŋāϤ⧇ āĻšā§ŸāĨ¤

Management Confidence: 0.94


🟩 PART 9 — ADVICE

Clinical Advice — āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ

1. Specialist Review: āĻĒ⧁āϰ⧋āύ⧋ injury-āĻāϰ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāϰ āϏāĻ™ā§āϗ⧇ āύāϤ⧁āύ āωāĻĒāϏāĻ°ā§āϗ⧇āϰ āĻŽāĻŋāϞ āφāϛ⧇ āĻ•āĻŋ āύāĻž āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ Orthopedic Knee Specialist-āĻāϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļāĨ¤

2. Imaging Review: āφāϗ⧇āϰ āĻ“ āύāϤ⧁āύ MRI/X-ray āĻĨāĻžāĻ•āϞ⧇ āϤ⧁āϞāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

3. Rehabilitation: Physiotherapist-āĻāϰ āϤāĻ¤ā§āĻ¤ā§āĻŦāĻžāĻŦāϧāĻžāύ⧇ āĻĒāĻ°ā§āϝāĻžā§ŸāĻ•ā§āϰāĻŽā§‡ Quadriceps StrengtheningāĨ¤

4. Medication Safety: āĻĒ⧁āϰ⧋āύ⧋ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻĻ⧇āϖ⧇ Aceclofenac āφāĻŦāĻžāϰ āύāĻŋāĻœā§‡ āĻĨ⧇āϕ⧇ āĻļ⧁āϰ⧁ āĻ•āϰāĻž āωāϚāĻŋāϤ āύ⧟āĨ¤

5. Avoid Duplicate NSAIDs: āĻāĻ•āĻžāϧāĻŋāĻ• NSAID āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϞ⧇ āϜāϟāĻŋāϞāϤāĻžāϰ āĻā§āρāĻ•āĻŋ āĻŦāĻžā§œā§‡āĨ¤

6. Warning Signs: āύāϤ⧁āύ āφāϘāĻžāϤ⧇āϰ āĻĒāϰ⧇ āĻĒāĻž āĻ āĻžāĻ¨ā§āĻĄāĻž āĻŦāĻž āĻ…āĻŦāĻļ āĻšā§Ÿā§‡ āϝāĻžāĻ“ā§ŸāĻž, āϤ⧀āĻŦā§āϰ āĻĢā§‹āϞāĻž, āĻšāĻžāρāϟ⧁āϤ⧇ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϞāĻ•ā§āώāĻŖ, āĻ•āĻŋāĻ‚āĻŦāĻž āĻĒāĻžā§Ÿā§‡ āĻ­āϰ āĻĻāĻŋāϤ⧇ āύāĻž āĻĒāĻžāϰāϞ⧇ āϜāϰ⧁āϰāĻŋ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Confidence: 0.96


🟧 PART 10 — CLINICAL PRESCRIPTION DEMONSTRATION

Educational Clinical Assessment & Prescription-Note Demo

DEMONSTRATION ONLY — NOT A VALID PRESCRIPTION OR MEDICATION ORDER

Department: Orthopedics & Trauma Surgery
Patient: Patient X
Age/Sex: Approximately 26 years / Male — historical document
Date of Review: 28 October 2026

C/C

Not documented in the historical prescription.

Possible symptoms to verify:

  • Chronic knee pain.
  • Subjective instability.
  • Functional difficulty.

H/O

  • Previous PCL injury — documented historically.
  • Previous tibial plateau fracture — documented historically.
  • Previous surgery and rehabilitation — unknown.

O/E

  • Possible thigh muscle wasting.
  • Possible positive posterior drawer test.
  • ROM and neurovascular examination — not documented.

Investigations

  • MRI of affected knee — historically requested.
  • Knee radiographs — historically requested.
  • Additional assessment based on current specialist examination.

Dx — Working Clinical Assessment

1. Old PCL Injury with Suspected Chronic PCL Insufficiency, Knee — Laterality to Confirm.

2. Suspected Post-Traumatic Knee Osteoarthritis Following Previous Tibial Plateau Fracture.

3. Possible Chronic Quadriceps Muscle Atrophy.

āĻŦāĻžāĻ‚āϞāĻž Dx

ā§§. āĻšāĻžāρāϟ⧁āϰ āĻĒ⧁āϰ⧋āύ⧋ PCL āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āĻŸā§‡āϰ āφāϘāĻžāϤ āĻāĻŦāĻ‚ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻ…āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻžāĨ¤

⧍. āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ Tibial Plateau Fracture-āĻāϰ āĻĒāϰ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āφāϘāĻžāϤāϜāύāĻŋāϤ āĻšāĻžāρāϟ⧁āϰ āĻ…āĻ¸ā§āϟāĻŋāĻ“āφāĻ°ā§āĻĨā§āϰāĻžāχāϟāĻŋāϏāĨ¤

ā§Š. āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻšāĻžāρāϟ⧁āϰ āϏāĻŽāĻ¸ā§āϝāĻžāϰ āĻ•āĻžāϰāϪ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Quadriceps Muscle AtrophyāĨ¤

Plan

  • Confirm laterality and current symptoms.
  • Review MRI and radiographs.
  • Assess PCL stability and functional impairment.
  • Begin or continue appropriate supervised rehabilitation after assessment.
  • Review analgesic need and NSAID risks.
  • Refer to Orthopedic Knee / Sports Injury Specialist.

Medication Documentation

Historical prescription contained:

Ternilla 100 mg, Maxpro MUPS 20 mg, Ostocal DX and Arthrosin TS.

Exact historical administration schedule and duration require verification from the original prescription or treating physician.

No new patient-specific medication order is issued in this demonstration.

Clinical Note Confidence: 0.84 for the provisional assessment.


🟩 PART 11 — APPROPRIATE REFERRAL

Which Doctor Should Manage This Patient?

Primary Referral

Orthopedic Surgeon — Knee Ligament & Sports Injury Specialist

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāρāϟ⧁āϰ āϞāĻŋāĻ—āĻžāĻŽā§‡āĻ¨ā§āϟ āĻ“ āĻĒ⧁āϰ⧋āύ⧋ āφāϘāĻžāϤ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āĻ…āĻ­āĻŋāĻœā§āĻž āĻ…āĻ°ā§āĻĨā§‹āĻĒ⧇āĻĄāĻŋāĻ• āϏāĻžāĻ°ā§āϜāύāĨ¤

Secondary Referral

Physical Medicine & Rehabilitation Specialist

āĻŦāĻžāĻ‚āϞāĻž: āĻĒ⧁āύāĻ°ā§āĻŦāĻžāϏāύ āĻ“ āĻŽāĻžāĻ‚āϏāĻĒ⧇āĻļāĻŋāϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āώāĻŽāϤāĻž āωāĻ¨ā§āύ⧟āύ⧇āϰ āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžāĨ¤

Physiotherapy

Musculoskeletal Physiotherapist

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāρāϟ⧁āϰ āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻž, āĻŽāĻžāĻ‚āϏāĻĒ⧇āĻļāĻŋāϰ āĻļāĻ•ā§āϤāĻŋ āĻ“ āĻĻ⧈āύāĻ¨ā§āĻĻāĻŋāύ āϚāϞāĻžāĻĢ⧇āϰāĻžāϰ āϏāĻ•ā§āώāĻŽāϤāĻž āωāĻ¨ā§āύ⧟āύ⧇āϰ āϜāĻ¨ā§āϝāĨ¤

Referral Confidence: 0.97


🟧 PART 12 — OVERVIEW / SUMMARY

āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻĨ⧇āϕ⧇ āĻŦā§‹āĻāĻž āϝāĻžāĻšā§āϛ⧇, āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻāĻ•āϟāĻŋ āĻĒ⧁āϰ⧋āύ⧋ āĻšāĻžāρāϟ⧁āϰ āφāϘāĻžāϤ, PCL Injury, Tibial Plateau Fracture āĻāĻŦāĻ‚ Knee Osteoarthritis-āĻāϰ āϏāĻŽāĻ¸ā§āϝāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰ⧇āĻ›āĻŋāϞ⧇āύāĨ¤

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Positive Posterior Drawer Test āĻ“ Thigh Muscle Wasting PCL-related chronic functional impairment-āĻāϰ āĻĒāĻ•ā§āώ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ Clinical ClueāĨ¤

āϤāĻŦ⧇ Imaging Results āύāĻž āĻĨāĻžāĻ•āĻžā§Ÿ PCL Tear-āĻāϰ Grade, Osteoarthritis-āĻāϰ Severity āĻāĻŦāĻ‚ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻšāĻžāρāϟ⧁āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§ŸāύāĻŋāĨ¤

Final Clinical Impression

Suspected Chronic PCL Insufficiency with Post-Traumatic Knee Osteoarthritis Following Previous Tibial Plateau Fracture.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒ⧁āϰ⧋āύ⧋ PCL āφāϘāĻžāϤāϜāύāĻŋāϤ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻšāĻžāρāϟ⧁āϰ āĻ…āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻž āĻāĻŦāĻ‚ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āϟāĻŋāĻŦāĻŋ⧟āĻžāϞ āĻĒā§āĻ˛ā§āϝāĻžāĻŸā§‹ āĻĢā§āĻ°ā§āϝāĻžāĻ•āϚāĻžāϰ⧇āϰ āĻĒāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ…āĻ¸ā§āϟāĻŋāĻ“āφāĻ°ā§āĻĨā§āϰāĻžāχāϟāĻŋāϏāĨ¤

Diagnostic Confidence: 0.76 — Provisional.


🟩 PART 13 — ACTIONABLE CLINICAL PLAN

Step 1: Identify the correct affected knee — āĻĄāĻžāύ āύāĻž āĻŦāĻžāĻŽ āĻšāĻžāρāϟ⧁ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻžāĨ¤

Step 2: Obtain original injury, treatment and operative history — āĻĒ⧁āϰ⧋āύ⧋ āφāϘāĻžāϤ āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āχāϤāĻŋāĻšāĻžāϏ āϏāĻ‚āĻ—ā§āϰāĻšāĨ¤

Step 3: Perform detailed knee examination — āĻšāĻžāρāϟ⧁āϰ āĻĒā§‚āĻ°ā§āĻŖāĻžāĻ™ā§āĻ— āĻĒāϰ⧀āĻ•ā§āώāĻžāĨ¤

Step 4: Review MRI and X-ray findings — āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ Imaging āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

Step 5: Assess functional instability and OA severity — āĻšāĻžāρāϟ⧁āϰ āĻ¸ā§āĻĨāĻŋāϤāĻŋāĻļā§€āϞāϤāĻž āĻ“ āĻ•ā§āĻˇā§Ÿā§‡āϰ āĻŽāĻžāĻ¤ā§āϰāĻž āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖāĨ¤

Step 6: Establish a tailored rehabilitation and pain-management plan — āϰ⧋āĻ—ā§€āϭ⧇āĻĻ⧇ āĻĒ⧁āύāĻ°ā§āĻŦāĻžāϏāύ āĻ“ āĻŦā§āϝāĻĨāĻž āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāĻŖāĨ¤

Step 7: Refer for surgical assessment only when indicated — āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϞ⧇ āϏāĻžāĻ°ā§āϜāĻŋāĻ•ā§āϝāĻžāϞ āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤

Plan Confidence: 0.95


📚 PART 14 — REFERENCE LIST

A. Medical Textbooks

1. Campbell’s Operative Orthopaedics.
14th Edition. Elsevier.
Relevant sections: Knee ligament injuries and post-traumatic joint disorders.

2. Bailey & Love’s Short Practice of Surgery.
27th Edition.
Relevant sections: Orthopaedic trauma, fracture management and joint disorders.

3. Harrison’s Principles of Internal Medicine.
21st Edition. McGraw Hill.
Relevant section: Osteoarthritis.

Textbook page numbers are intentionally omitted because exact pagination has not been independently verified.

B. International Clinical Guidelines

4. NICE Guideline NG226 (2022).
Osteoarthritis in over 16s: Diagnosis and Management.

NICE NG226 Official Recommendations

5. American College of Rheumatology/Arthritis Foundation (2019 Guideline; published 2020).

Management of Osteoarthritis of the Hand, Hip, and Knee.

DOI: 10.1002/acr.24131

C. Peer-Reviewed Journals — Verified DOI

6. Verhulst FV, MacDonald P. (2020).
Diagnosing PCL Injuries: History, Physical Examination, Imaging Studies, Arthroscopic Evaluation.

Sports Medicine and Arthroscopy Review.

DOI: 10.1097/JSA.0000000000000251

7. Cook CR, Wissman RD. (2021).
Imaging Review of the Posterior Cruciate Ligament.

Journal of Knee Surgery.

DOI: 10.1055/s-0040-1722629

8. Aurich M, Koenig V, Hofmann G. (2018).
Comminuted Intraarticular Fractures of the Tibial Plateau Lead to Posttraumatic Osteoarthritis of the Knee.

Asian Journal of Surgery.

DOI: 10.1016/j.asjsur.2016.11.011

9. Kolasinski SL, et al. (2020).
2019 American College of Rheumatology/Arthritis Foundation Guideline for Management of Osteoarthritis.

Arthritis & Rheumatology.

DOI: 10.1002/art.41142

10. Wilebski BJ, et al. (2026).
Current Standards for Objective Assessment and Management of Posterior Cruciate Ligament Tears: A Narrative Review.

Annals of Joint.

DOI: 10.21037/aoj-25-52

D. Bangladesh Drug Information

11. MedEx Bangladesh.

Verified brand monographs:

  • Ternilla 100 mg.
  • Maxpro MUPS 20 mg.
  • Ostocal DX.
  • Arthrosin TS.

FINAL PUBLICATION DECLARATION

This article represents a retrospective interpretation of an uploaded historical prescription. It does not establish the patient’s current diagnosis, reproduce an independently verified examination or substitute for specialist evaluation.

Confidence values are qualitative assessments of evidence and transcription certainty, not statistically validated diagnostic probabilities.


Author Name: Md.Rafiqul Islam Lipu
Publication: LIPU MED — Clinical Prescription Review
Website: raiyyantahsan.com
Department: Orthopedics & Trauma Surgery
Date: Wednesday, 28 October 2026
Time: 02:11 PM (Bangladesh Standard Time, UTC+06:00)
Status: Educational Clinical Case Review — Provisional Diagnosis

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top